- Home
- KLRS vs OPAD Comparison
KLRS vs OPAD Comparison
Compare KLRS & OPAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- OPAD
- Stock Information
- Founded
- KLRS 2019
- OPAD 2015
- Country
- KLRS United States
- OPAD United States
- Employees
- KLRS N/A
- OPAD N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- OPAD Real Estate
- Sector
- KLRS Health Care
- OPAD Finance
- Exchange
- KLRS Nasdaq
- OPAD Nasdaq
- Market Cap
- KLRS 46.0M
- OPAD 43.7M
- IPO Year
- KLRS N/A
- OPAD N/A
- Fundamental
- Price
- KLRS $3.71
- OPAD $4.28
- Analyst Decision
- KLRS Strong Buy
- OPAD Hold
- Analyst Count
- KLRS 2
- OPAD 5
- Target Price
- KLRS $23.00
- OPAD $2.41
- AVG Volume (30 Days)
- KLRS 689.3K
- OPAD 24.1M
- Earning Date
- KLRS 11-15-2025
- OPAD 11-03-2025
- Dividend Yield
- KLRS N/A
- OPAD N/A
- EPS Growth
- KLRS N/A
- OPAD N/A
- EPS
- KLRS N/A
- OPAD N/A
- Revenue
- KLRS N/A
- OPAD $703,352,000.00
- Revenue This Year
- KLRS N/A
- OPAD N/A
- Revenue Next Year
- KLRS N/A
- OPAD $23.26
- P/E Ratio
- KLRS N/A
- OPAD N/A
- Revenue Growth
- KLRS N/A
- OPAD N/A
- 52 Week Low
- KLRS $2.14
- OPAD $0.91
- 52 Week High
- KLRS $24.15
- OPAD $6.35
- Technical
- Relative Strength Index (RSI)
- KLRS 52.79
- OPAD 56.72
- Support Level
- KLRS $2.37
- OPAD $3.75
- Resistance Level
- KLRS $4.90
- OPAD $5.44
- Average True Range (ATR)
- KLRS 0.70
- OPAD 1.15
- MACD
- KLRS -0.02
- OPAD -0.06
- Stochastic Oscillator
- KLRS 24.95
- OPAD 33.01
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About OPAD Offerpad Solutions Inc.
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services including mortgage, listing, renovation and buyer representation services.